254 related articles for article (PubMed ID: 31920114)
1. Switching Pharmacological Treatment in Wilson Disease: Case Report and Recommendations.
Leung M; Wu Lanzafame J; Medici V
J Investig Med High Impact Case Rep; 2020; 8():2324709619896876. PubMed ID: 31920114
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
Appenzeller-Herzog C; Mathes T; Heeres MLS; Weiss KH; Houwen RHJ; Ewald H
Liver Int; 2019 Nov; 39(11):2136-2152. PubMed ID: 31206982
[TBL] [Abstract][Full Text] [Related]
4. Trientine induced colitis during therapy for Wilson disease: a case report and review of the literature.
Boga S; Jain D; Schilsky ML
BMC Pharmacol Toxicol; 2015 Nov; 16():30. PubMed ID: 26589720
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
[TBL] [Abstract][Full Text] [Related]
6. Zinc Therapy for Wilson Disease in Children in French Pediatric Centers.
Santiago R; Gottrand F; Debray D; Bridoux L; Lachaux A; Morali A; Lapeyre D; Lamireau T
J Pediatr Gastroenterol Nutr; 2015 Dec; 61(6):613-8. PubMed ID: 26230903
[TBL] [Abstract][Full Text] [Related]
7. Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy.
Seessle J; Gotthardt DN; Schäfer M; Gohdes A; Pfeiffenberger J; Ferenci P; Stremmel W; Weiss KH
J Inherit Metab Dis; 2016 Jan; 39(1):125-30. PubMed ID: 26067812
[TBL] [Abstract][Full Text] [Related]
8. Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson's disease in resource constrained setting.
Gupta P; Choksi M; Goel A; Zachariah U; Sajith KG; Ramachandran J; Chandy G; Kurian G; Rebekah G; Eapen CE
Indian J Gastroenterol; 2018 Jan; 37(1):31-38. PubMed ID: 29457214
[TBL] [Abstract][Full Text] [Related]
9. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.
Schilsky ML; Czlonkowska A; Zuin M; Cassiman D; Twardowschy C; Poujois A; Gondim FAA; Denk G; Cury RG; Ott P; Moore J; Ala A; D'Inca R; Couchonnal-Bedoya E; D'Hollander K; Dubois N; Kamlin COF; Weiss KH;
Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1092-1102. PubMed ID: 36183738
[TBL] [Abstract][Full Text] [Related]
10. [Wilson disease: an update].
Seo JK
Korean J Hepatol; 2006 Sep; 12(3):333-63. PubMed ID: 16998287
[TBL] [Abstract][Full Text] [Related]
11. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
[TBL] [Abstract][Full Text] [Related]
12. Response to different therapeutic approaches in Wilson disease. A long-term follow up study.
Rodríguez B; Burguera J; Berenguer M
Ann Hepatol; 2012; 11(6):907-14. PubMed ID: 23109455
[TBL] [Abstract][Full Text] [Related]
13. Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment.
Pfeiffenberger J; Lohse CM; Gotthardt D; Rupp C; Weiler M; Teufel U; Weiss KH; Gauss A
J Inherit Metab Dis; 2019 Mar; 42(2):371-380. PubMed ID: 30746719
[TBL] [Abstract][Full Text] [Related]
14. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment.
Arnon R; Calderon JF; Schilsky M; Emre S; Shneider BL
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):596-602. PubMed ID: 17460493
[TBL] [Abstract][Full Text] [Related]
15. Multicentre, retrospective study to assess long-term outcomes of chelator based treatment with trientine in Wilson disease patients withdrawn from therapy with d -penicillamine.
Weiss KH; Kruse C; Manolaki N; Zuin M; Ferenci P; van Scheppingen D; Wijnberg L; de Koning CE; Dhawan A
Eur J Gastroenterol Hepatol; 2022 Sep; 34(9):940-947. PubMed ID: 35482910
[TBL] [Abstract][Full Text] [Related]
16. Wilson disease - currently used anticopper therapy.
Członkowska A; Litwin T
Handb Clin Neurol; 2017; 142():181-191. PubMed ID: 28433101
[TBL] [Abstract][Full Text] [Related]
17. Trientine-induced neurological deterioration in a patient with Wilson's disease.
Kim B; Chung SJ; Shin HW
J Clin Neurosci; 2013 Apr; 20(4):606-8. PubMed ID: 23274038
[TBL] [Abstract][Full Text] [Related]
18. Oral complications associated with D-penicillamine treatment for Wilson disease: a clinicopathologic report.
Tovaru S; Parlatescu I; Dumitriu AS; Bucur A; Kaplan I
J Periodontol; 2010 Aug; 81(8):1231-6. PubMed ID: 20384464
[TBL] [Abstract][Full Text] [Related]
19. [A study of trientine therapy in Wilson's disease with neurological symptoms].
Suda M; Kubota J; Yamaguchi Y; Fujioka Y; Saito Y; Aoki T
No To Hattatsu; 1993 Sep; 25(5):429-34. PubMed ID: 8398232
[TBL] [Abstract][Full Text] [Related]
20. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease.
Siegemund R; Lössner J; Günther K; Kühn HJ; Bachmann H
Acta Neurol Scand; 1991 Jun; 83(6):364-6. PubMed ID: 1887758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
